International Journal of Endocrinology / 2015 / Article / Tab 1 / Research Article
Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin Table 1 Indices of glycemic control quality and glycemic variability in patients with type 2 diabetes after placebo and after vildagliptin (data are mean ± SE). For the explanation of the various indices see the Methods section.
Placebo Vildagliptin valueIndices of glycemic control quality Mean (mmol/L) 8.11 ± 0.25 7.36 ± 0.23 <0.0001 Maximum (mmol/L) 16.37 ± 1.80 13.54 ± 0.66 0.007 Minimum (mmol/L) 3.76 ± 0.20 3.66 ± 0.19 0.37 50th percentile (median) (mmol/L) 7.82 ± 0.25 7.13 ± 0.24 0.0001 Percentage below target (3.9 mmol/L) (%) 2.0 ± 0.6 3.1 ± 0.9 0.055 Percentage in target (3.9–11.1 mmol/L) (%) 86.1 ± 2.4 89.8 ± 2.2 0.062 Percentage above target (11.1 mmol/L) (%) 11.9 ± 2.3 7.0 ± 2.0 0.002 GRADE (unitless) 6.61 ± 0.59 5.17 ± 0.52 <0.0001 M-VALUE (unitless) 6.22 ± 1.18 4.97 ± 0.95 0.004 Hypoglycemia index (unitless) 7.67 ± 1.45 5.66 ± 1.07 0.093 Hyperglycemia index (unitless) 1.97 ± 0.20 1.61 ± 0.20 0.002 IGC (unitless) 9.81 ± 1.32 7.32 ± 1.04 0.059 LBGI (unitless) 0.64 ± 0.15 1.03 ± 0.20 0.002 HBGI (unitless) 4.57 ± 0.66 3.12 ± 0.56 <0.0001 ADRR (unitless) 45.0 ± 7.3 35.5 ± 3.8 0.043 Indices of glycemic variability Standard deviation (mmol/L) 2.27 ± 0.21 2.00 ± 0.17 0.015 Interquartile range (mmol/L) 2.87 ± 0.24 2.68 ± 0.26 0.092 CONGA (mmol/L) 3.12 ± 0.29 2.71 ± 0.22 0.011 J-INDEX (10−3 (mmol/L)2 ) 0.12 ± 0.01 0.09 ± 0.01 <0.0001 MAGE (mmol/L) 4.80 ± 0.48 4.16 ± 0.33 0.010 MAGE (pos.) (mmol/L) 4.82 ± 0.48 4.20 ± 0.32 0.020 MAGE (neg.) (mmol/L) 4.77 ± 0.47 4.13 ± 0.35 0.007